Birdwatch Note Rating
2023-05-20 22:25:11 UTC - HELPFUL
Rated by Participant: CA817A074F6A88E416EDA42C6CDFE36F61F456E821903E60D298A536B33EE5B2
Participant Details
Original Note:
A phase three trial found Pfizer’s shot was nearly 82% effective at preventing severe disease from RSV in newborns during the first 90 days of life. RSV is a leading cause of hospitalization in children <1 year of age. https://pubmed.ncbi.nlm.nih.gov/23878043/ https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-phase-3-global
All Note Details